Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$9.63B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  BIIB
Biogen
BIIB
61 / 100
S&P500
$201.72arrow_drop_up4.42%$8.54

Performance History

Stocklytics logo
Key Stats
Open$193.34
Prev. Close$194.11
EPS7.96
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$28.31B
PE Ratio24.27
LOWHIGH
Day Range192.75
195.86
52 Week Range189.44
319.76
Ratios
P/B Ratio1.95
Revenue$9.83B
Operating M. %19.32%
Earnings$1.16B
Earnings Growth %-60.78%
EBITDA Margin %24.17%
ROE %8.24%
EPS7.96

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

61vs 54. Market Avg.

All Score 61 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

BIIBMARKET
Value5340
Quality5540
Ownership4017
Growth4747
Dividends-38
check_circle

Biogen 's Price discount from 1 year high of 38.98% is great compared to market average of 19.17%. This indicates BIIB could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$745.69
24H (%)arrow_drop_up1.96%
24H ($)$14.35
MARKET CAP$695.32B
PRICE$486.17
24H (%)arrow_drop_down1.02%
24H ($)-$5.05
MARKET CAP$452.88B
PRICE$149.56
24H (%)arrow_drop_up0.29%
24H ($)$0.44
MARKET CAP$359.34B
PRICE$126.88
24H (%)arrow_drop_down0.04%
24H ($)-$0.06
MARKET CAP$321.54B

About Biogen (BIIB)

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Drug Manufacturers—General
CEO
Mr. Christopher A. Viehbacher
Headquarters
Cambridge
Employees
8725
Exchange
NASDAQ
add Biogen  to watchlist

Keep an eye on Biogen

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Biogen 's (BIIB) price per share?

The current price per share for Biogen (BIIB) is $193.18. The stock has seen a price change of -$0.93 recently, indicating a -0.48% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Biogen (BIIB)?

For Biogen (BIIB), the 52-week high is $319.76, which is 65.52% from the current price. The 52-week low is $189.44, the current price is 1.97% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Biogen (BIIB) a growth stock?

Biogen (BIIB) has shown an average price growth of -5.16% over the past three years. It has received a score of 47 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Biogen as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Biogen (BIIB) stock price performance year to date (YTD)?

As of the latest data, Biogen (BIIB) has a year-to-date price change of -27.84%. Over the past month, the stock has experienced a price change of -10.81%. Over the last three months, the change has been -21.8%. Over the past six months, the figure is -23.37%. Looking at a longer horizon, the five-year price change stands at -13.91%.

help
Is Biogen (BIIB) a profitable company?

Biogen (BIIB) has a net income of $1.16B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 74.24% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 19.32% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $9.84B, although specific revenue growth data is currently not available. The gross profit is $7.3B. Operating income is noted at $1.3B. Furthermore, the EBITDA is $2.6B.

help
What is the market capitalization of Biogen (BIIB)?

Biogen (BIIB) has a market capitalization of $28.32B. The average daily trading volume is 1.22M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.